Formula I MSC Composition for Ischemic Heart Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for regenerating heart muscle tissue after myocardial infarction are inadequate due to the inability of transplanted cells to survive in ischemic regions, lack of early blood supply reconstitution, and poor cardiomyogenic differentiation efficiency, leading to irreversible scar formation and poor functional recovery.
Innovation Solution
A pharmaceutical composition comprising compounds of Formula (I) is used to enhance the survival potential and cardiogenic differentiation efficiency of mesenchymal stem cells (MSCs) ex vivo, followed by transplantation or administration of conditioned medium containing secretory proteins to promote heart tissue regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transplanted MSCs are used to regenerate heart tissue, then myocardial regeneration is promoted, but the transplanted cells fail to survive in ischemic regions
Solution Approach 1:
The patent applies preliminary action by pre-treating MSCs with compounds of Formula (I) before transplantation to enhance their survival potential. The compounds are administered to MSCs in vitro prior to implantation, allowing the cells to be pre-conditioned and better equipped to withstand ischemic conditions in the infarcted heart tissue.
Solution Approach 2:
The patent employs parameter changes by modifying the biochemical environment of MSCs through compound treatment. The compounds alter cellular parameters such as proliferation capacity, differentiation efficiency, and survival mechanisms, transforming the cells into a more resilient state capable of thriving in ischemic conditions.
2Quantity of substance
If MSCs are transplanted alone, then some angiogenesis and myogenesis occur, but regeneration is limited to border zones with adequate blood supply
Solution Approach 1:
The patent applies preliminary action by pre-treating MSCs with compounds of Formula (I) before transplantation to enhance their survival potential. The compounds are administered to MSCs in vitro prior to implantation, allowing the cells to be pre-conditioned and better equipped to withstand ischemic conditions in the infarcted heart tissue.
Solution Approach 2:
The patent employs parameter changes by modifying the biochemical environment of MSCs through compound treatment. The compounds alter cellular parameters such as proliferation capacity, differentiation efficiency, and survival mechanisms, transforming the cells into a more resilient state capable of thriving in ischemic conditions.
3Reliability
If exogenous Akt is overexpressed in MSCs, then survival potential is enhanced, but cardiomyogenic differentiation efficiency remains poor
Solution Approach 1:
The patent employs parameter changes by using compounds of Formula (I) that simultaneously modulate multiple cellular parameters. Unlike exogenous Akt overexpression which only affects survival, these compounds adjust a broader range of biochemical parameters including proliferation, differentiation, and survival, achieving a balanced improvement in both survival potential and cardiomyogenic differentiation efficiency.
Solution Approach 2:
The patent applies composite materials by using a combination of compounds with different mechanisms of action. The compounds work synergistically to enhance both survival and differentiation, creating a composite therapeutic effect that overcomes the limitation of single-mechanism approaches like exogenous Akt overexpression.
Data Source
AI summary
A pharmaceutical composition and method for regenerating cardiomyocytes in treating or repairing heart muscle damages cause by an ischemic disease. The pharmaceutical composition contains an active ingredient compound with a backbone structure of Formula (I). The active ingredient compound is capable of (a) increasing viability of myogenic precursor cells to enable said precursor cells to survive through an absolute ischemic period; (b) reconstituting a damaged blood supply network in said heart region where said injured muscle is located; and (c) enhancing cardiomyogenic differentiation efficiency of said precursor cells down cardiac linage, said steps being performed simultaneously or in any particular order.